Umeclidinium Bromide
Brand names: Incruse Ellipta
At a glance
- Medicare prescriptions, 2024
- 561,189
- Medicare drug cost
- $233.3M
- Average cost per prescription
- $416
- Clinicians who prescribed it
- 22,840
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
From the FDA-approved prescribing information (label dated December 2023). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Pulmonology 30.2%
- Family Medicine 20.3%
- Internal Medicine 19.3%
- Nurse Practitioners 16.0%
- Physician Assistants 5.1%
- Critical Care Medicine 3.4%
- Geriatric Medicine 1.7%
- Allergy & Immunology 0.9%
- Hospitalist 0.6%
- General Practice 0.5%
- Infectious Disease 0.3%
- Sleep Medicine 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 36% from 2019 to 2024.
Biggest change by state since 2019
- Colorado +9%
- Oregon −2%
- Rhode Island −9%
- Wisconsin −15%
- New Jersey −17%
- Mississippi (smallest change) −67%
- Louisiana (smallest change) −64%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.